Evidence Gaps in Total Hip Arthroplasty: A Registry-Based Study of Trial Discontinuation and Nonpublication From 2000 to 2024
- 1College of Osteopathic Medicine, Des Moines University, Des Moines, USA
- 2College of Osteopathic Medicine, Kansas City University, Kansas City, USA
- 3Department of Orthopedic Surgery, Valley Hospital Medical Center, Las Vegas, USA
Abstract
Background
Clinical trials play a vital role in advancing evidence-based orthopedic care, yet trial discontinuation and nonpublication limit transparency and reduce the availability of clinically valuable data. In total hip arthroplasty (THA), incomplete dissemination of trial outcomes may have important ethical and clinical implications.
Methods
A registry-based cross-sectional analysis of randomized Phase III and IV THA clinical trials registered on ClinicalTrials.gov between 2000 and 2024 was performed. Trials registered at least two years before the search date (January 2026) were included. Trial characteristics, including funding source, intervention type, enrollment size, blinding, number of centers, and recruitment location, were extracted. Publication status was determined through registry-linked publications and independent database searches. Associations were analyzed using chi-square or Fisher’s exact tests (p < 0.05).
Results
Of 168 identified trials, seven unrelated to THA were excluded, leaving 161 trials for analysis. Fifty trials (31.1%) were discontinued, and 111 (68.9%) were completed. Among completed trials, 26 (23.4%) remained unpublished. Discontinuation was significantly associated with intervention type (p = 0.0015) and blinding (p = 0.022), with higher rates in device trials (59.3%) and unblinded studies (55.9%). Nonpublication was significantly associated with industry funding (39.3% vs. 18.1%, p = 0.022) and intervention type (p = 0.044).
Conclusions
A substantial proportion of THA clinical trials are discontinued or remain unpublished, contributing to data loss and potential bias in the orthopedic literature. Improved reporting compliance is needed to support transparency and evidence-based orthopedic practice.
Related
- Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―
- Customized glenoid implants in reverse total shoulder arthroplasty: assessing revision rate and causes of failure in the Australian Joint Registry
- Supraspinatus management in reverse total shoulder arthroplasty for proximal humerus fractures: current evidence and practical considerations.
- Prevention and management of kinesiophobia after total knee arthroplasty: an evidence-informed narrative review and proposed stepped-care pathway
- Distinguishing artificial intelligence from robotic execution in total knee arthroplasty: a narrative review and evidence map
BibTeX
@article{sautter2026evidence,
title = {{Evidence Gaps in Total Hip Arthroplasty: A Registry-Based Study of Trial Discontinuation and Nonpublication From 2000 to 2024}},
author = {Carson R Sautter and Daxton J Kennington and Mark Gamadia and Alexis Ortega and Connor Parry and Keith Kotecki},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117850},
url = {https://doi.org/10.7759/cureus.117850},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evidence Gaps in Total Hip Arthroplasty: A Registry-Based Study of Trial Discontinuation and Nonpublication From 2000 to 2024
AU - Carson R Sautter
AU - Daxton J Kennington
AU - Mark Gamadia
AU - Alexis Ortega
AU - Connor Parry
AU - Keith Kotecki
PY - 2026
DA - 2026/10/13
JO - Cureus
DO - 10.7759/cureus.117850
UR - https://doi.org/10.7759/cureus.117850
AB - Background Clinical trials play a vital role in advancing evidence-based orthopedic care, yet trial discontinuation and nonpublication limit transparency and reduce the availability of clinically valuable data. In total hip arthroplasty (THA), incomplete dissemination of trial outcomes may have important ethical and clinical implications. Methods A registry-based cross-sectional analysis of randomized Phase III and IV THA clinical trials registered on ClinicalTrials.gov between 2000 and 2024 was performed. Trials registered at least two years before the search date (January 2026) were included. Trial characteristics, including funding source, intervention type, enrollment size, blinding, number of centers, and recruitment location, were extracted. Publication status was determined through registry-linked publications and independent database searches. Associations were analyzed using chi-square or Fisher’s exact tests (p < 0.05). Results Of 168 identified trials, seven unrelated to THA were excluded, leaving 161 trials for analysis. Fifty trials (31.1%) were discontinued, and 111 (68.9%) were completed. Among completed trials, 26 (23.4%) remained unpublished. Discontinuation was significantly associated with intervention type (p = 0.0015) and blinding (p = 0.022), with higher rates in device trials (59.3%) and unblinded studies (55.9%). Nonpublication was significantly associated with industry funding (39.3% vs. 18.1%, p = 0.022) and intervention type (p = 0.044). Conclusions A substantial proportion of THA clinical trials are discontinued or remain unpublished, contributing to data loss and potential bias in the orthopedic literature. Improved reporting compliance is needed to support transparency and evidence-based orthopedic practice.
SN - 2168-8184
ER -